Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study

BMJ 2010; 340 doi: (Published 11 June 2010)
Cite this as: BMJ 2010;340:c2459

Related articles

Endgames: Odds and odds ratios

Research: Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study

Analysis: Implications of “not me” drugs for health systems: lessons from age related macular degeneration

Letter: A matter of public interest

Editorial: Bevacizumab for the treatment of neovascular age related macular degeneration

Paper: Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

See more

Research: Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis

Editorial: PSA screening for prostate cancer

Editorial: Does US health reform reduce hospital readmission rates?

This article has been cited by other articles: